Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 5, 2026
- Disc Medicine’s APOLLO trial of bitopertin met all primary and secondary endpoints in EPP; NDA resubmission is planned by end of 2026, while approximately $486 million in October 2026 offering proceeds extend cash runway into 2030.
- 10-Q report · filed Nov 5, 2026
- Disc Medicine reported positive APOLLO Phase 3 results for bitopertin and plans an NDA resubmission by the end of 2026. Cash, cash equivalents and marketable securities totaled $682.8 million at September 30, 2026, funding is expected into 2030.
The audio replay and transcript follow the call.